Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Receivables - Other (2019 - 2025)

Neurocrine Biosciences filings provide 7 years of Receivables - Other readings, the most recent being $20.5 million for Q4 2025.

  • On a quarterly basis, Receivables - Other rose 42.36% to $20.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.5 million, a 42.36% increase, with the full-year FY2025 number at $20.5 million, up 42.36% from a year prior.
  • Receivables - Other hit $20.5 million in Q4 2025 for Neurocrine Biosciences, up from $14.4 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $20.5 million in Q4 2025 to a low of $2.2 million in Q4 2021.
  • Median Receivables - Other over the past 5 years was $4.4 million (2023), compared with a mean of $6.8 million.
  • Biggest five-year swings in Receivables - Other: plummeted 40.54% in 2021 and later soared 186.36% in 2024.
  • Neurocrine Biosciences' Receivables - Other stood at $2.2 million in 2021, then surged by 113.64% to $4.7 million in 2022, then skyrocketed by 138.3% to $11.2 million in 2023, then rose by 28.57% to $14.4 million in 2024, then surged by 42.36% to $20.5 million in 2025.
  • The last three reported values for Receivables - Other were $20.5 million (Q4 2025), $14.4 million (Q4 2024), and $12.6 million (Q1 2024) per Business Quant data.